 |
PDBsum entry 1e4j
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Immune system
|
PDB id
|
|
|
|
1e4j
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Nature
406:267-273
(2000)
|
|
PubMed id:
|
|
|
|
|
| |
|
The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex.
|
|
P.Sondermann,
R.Huber,
V.Oosthuizen,
U.Jacob.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The immune response depends on the binding of opsonized antigens to cellular Fc
receptors and the subsequent initiation of various cellular effector functions
of the immune system. Here we describe the crystal structures of a soluble Fc
gamma receptor (sFc gammaRIII, CD16), an Fc fragment from human IgG1 (hFc1) and
their complex. In the 1:1 complex the receptor binds to the two halves of the Fc
fragment in contact with residues of the C gamma2 domains and the hinge region.
Upon complex formation the angle between the two sFc gammaRIII domains increases
significantly and the Fc fragment opens asymmetrically. The high degree of amino
acid conservation between sFc gammaRIII and other Fc receptors, and similarly
between hFc1 and related immunoglobulins, suggest similar structures and modes
of association. Thus the described structure is a model for immune complex
recognition and helps to explain the vastly differing affinities of other Fc
gammaR-IgG complexes and the Fc epsilonRI alpha-IgE complex.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1: The overall structure of the sFc bold gamma- RIII-hFc1
complex. a, Stereo ribbon representation with the dimer axis
of hFc1 (red and blue) orientated vertically. The 'proline
sandwich' consisting of Pro 329 of the C 2-A
domain and Trp 87 and Trp 110 of sFc RIII
(green) is shown in ball and stick together with the
carbohydrate residues of the Fc fragment and the interchain
disulphide bridge (yellow) of the Cys 229 residues. The
potential N-glycosylation sites in sFc RIII
are shown as cyan balls. b, Side view of the complex obtained by
a rotation of 90° around the y axis. Unless indicated, all
figures were produced with the programs MOLSCRIPT46 and
RASTER3D^47.
|
 |
Figure 2.
Figure 2: Superposition of the complexed components with the
free structures (C alpha- trace).
a, sFc RIII
in complexed form (cyan) was superimposed with a least square
algorithm using the C atoms
of the first domain onto the structure of sFc RIII
obtained from sFc RIII
crystals (magenta). Trp 95 and Tyr 14 which form a new hydrogen
bond upon complex formation are shown in ball and stick
representation b, Overlay of the hFc1 structures obtained from
the complex (cyan) and from hFc1 crystals (magenta). For the
superposition the C atoms
of both C 3
domains were used. The orientation of the structures is the same
as in Fig. 1a.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nature
(2000,
406,
267-273)
copyright 2000.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
P.M.Hogarth,
and
G.A.Pietersz
(2012).
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.
|
| |
Nat Rev Drug Discov,
11,
311-331.
|
 |
|
|
|
|
 |
A.W.Barb,
and
J.H.Prestegard
(2011).
NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic.
|
| |
Nat Chem Biol,
7,
147-153.
|
 |
|
|
|
|
 |
E.Karaca,
and
A.M.Bonvin
(2011).
A multidomain flexible docking approach to deal with large conformational changes in the modeling of biomolecular complexes.
|
| |
Structure,
19,
555-565.
|
 |
|
|
|
|
 |
J.Lu,
K.D.Marjon,
L.L.Marnell,
R.Wang,
C.Mold,
T.W.Du Clos,
and
P.Sun
(2011).
Recognition and functional activation of the human IgA receptor (FcalphaRI) by C-reactive protein.
|
| |
Proc Natl Acad Sci U S A,
108,
4974-4979.
|
 |
|
|
|
|
 |
M.D.Holdom,
A.M.Davies,
J.E.Nettleship,
S.C.Bagby,
B.Dhaliwal,
E.Girardi,
J.Hunt,
H.J.Gould,
A.J.Beavil,
J.M.McDonnell,
R.J.Owens,
and
B.J.Sutton
(2011).
Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI.
|
| |
Nat Struct Mol Biol,
18,
571-576.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Lisi,
M.Sisto,
D.D.Lofrumento,
S.D'Amore,
and
M.D'Amore
(2011).
Advances in the understanding of the Fc gamma receptors-mediated autoantibodies uptake.
|
| |
Clin Exp Med,
11,
1.
|
 |
|
|
|
|
 |
X.R.Jiang,
A.Song,
S.Bergelson,
T.Arroll,
B.Parekh,
K.May,
S.Chung,
R.Strouse,
A.Mire-Sluis,
and
M.Schenerman
(2011).
Advances in the assessment and control of the effector functions of therapeutic antibodies.
|
| |
Nat Rev Drug Discov,
10,
101-111.
|
 |
|
|
|
|
 |
Y.A.Kovalitskaya,
and
E.V.Navolotskaya
(2011).
Nonopioid Effect of β-Endorphin.
|
| |
Biochemistry (Mosc),
76,
379-393.
|
 |
|
|
|
|
 |
D.K.Nayak,
A.Tang,
M.Wilson,
N.W.Miller,
and
E.Bengtén
(2010).
Channel catfish soluble FcmuR binds conserved linear epitopes present on Cmu3 and Cmu4.
|
| |
Mol Immunol,
47,
1306-1316.
|
 |
|
|
|
|
 |
H.H.von Horsten,
C.Ogorek,
V.Blanchard,
C.Demmler,
C.Giese,
K.Winkler,
M.Kaup,
M.Berger,
I.Jordan,
and
V.Sandig
(2010).
Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.
|
| |
Glycobiology,
20,
1607-1618.
|
 |
|
|
|
|
 |
H.Nagashima,
and
Y.Masuho
(2010).
[Enhancement of antibody-dependent cellular cytotoxicity by tandem Fc multimerization]
|
| |
Yakugaku Zasshi,
130,
49-54.
|
 |
|
|
|
|
 |
K.G.Smith,
and
M.R.Clatworthy
(2010).
FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.
|
| |
Nat Rev Immunol,
10,
328-343.
|
 |
|
|
|
|
 |
S.Lightle,
S.Aykent,
N.Lacher,
V.Mitaksov,
K.Wells,
J.Zobel,
and
T.Oliphant
(2010).
Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding.
|
| |
Protein Sci,
19,
753-762.
|
 |
|
|
|
|
 |
S.T.Jung,
T.H.Kang,
and
G.Georgiou
(2010).
Efficient expression and purification of human aglycosylated Fcgamma receptors in Escherichia coli.
|
| |
Biotechnol Bioeng,
107,
21-30.
|
 |
|
|
|
|
 |
Y.Machino,
H.Ohta,
E.Suzuki,
S.Higurashi,
T.Tezuka,
H.Nagashima,
J.Kohroki,
and
Y.Masuho
(2010).
Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP).
|
| |
Clin Exp Immunol,
162,
415-424.
|
 |
|
|
|
|
 |
A.Natsume,
R.Niwa,
and
M.Satoh
(2009).
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.
|
| |
Drug Des Devel Ther,
3,
7.
|
 |
|
|
|
|
 |
C.A.McElroy,
J.A.Dohm,
and
S.T.Walsh
(2009).
Structural and biophysical studies of the human IL-7/IL-7Ralpha complex.
|
| |
Structure,
17,
54-65.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
E.Mehlhop,
S.Nelson,
C.A.Jost,
S.Gorlatov,
S.Johnson,
D.H.Fremont,
M.S.Diamond,
and
T.C.Pierson
(2009).
Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.
|
| |
Cell Host Microbe,
6,
381-391.
|
 |
|
|
|
|
 |
M.Schlapschy,
M.Fogarasi,
H.Gruber,
O.Gresch,
C.Schäfer,
Y.Aguib,
and
A.Skerra
(2009).
Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains.
|
| |
Protein Eng Des Sel,
22,
175-188.
|
 |
|
|
|
|
 |
M.Shibata-Koyama,
S.Iida,
A.Okazaki,
K.Mori,
K.Kitajima-Miyama,
S.Saitou,
S.Kakita,
Y.Kanda,
K.Shitara,
K.Kato,
and
M.Satoh
(2009).
The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
|
| |
Glycobiology,
19,
126-134.
|
 |
|
|
|
|
 |
N.Yamane-Ohnuki,
and
M.Satoh
(2009).
Production of therapeutic antibodies with controlled fucosylation.
|
| |
MAbs,
1,
230-236.
|
 |
|
|
|
|
 |
R.Jefferis
(2009).
Glycosylation as a strategy to improve antibody-based therapeutics.
|
| |
Nat Rev Drug Discov,
8,
226-234.
|
 |
|
|
|
|
 |
R.Jefferis
(2009).
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action.
|
| |
Trends Pharmacol Sci,
30,
356-362.
|
 |
|
|
|
|
 |
S.Bonetto,
L.Spadola,
A.G.Buchanan,
L.Jermutus,
and
J.Lund
(2009).
Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human Fc gammaRI.
|
| |
FASEB J,
23,
575-585.
|
 |
|
|
|
|
 |
Y.Luo,
Z.Lu,
S.W.Raso,
C.Entrican,
and
B.Tangarone
(2009).
Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors.
|
| |
MAbs,
1,
491-504.
|
 |
|
|
|
|
 |
E.R.Sprague,
H.Reinhard,
E.J.Cheung,
A.H.Farley,
R.D.Trujillo,
H.Hengel,
and
P.J.Bjorkman
(2008).
The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G.
|
| |
J Virol,
82,
3490-3499.
|
 |
|
|
|
|
 |
F.Nimmerjahn,
and
J.V.Ravetch
(2008).
Fcgamma receptors as regulators of immune responses.
|
| |
Nat Rev Immunol,
8,
34-47.
|
 |
|
|
|
|
 |
M.M.Gomes,
S.B.Wall,
K.Takahashi,
J.Novak,
M.B.Renfrow,
and
A.B.Herr
(2008).
Analysis of IgA1 N-glycosylation and its contribution to FcalphaRI binding.
|
| |
Biochemistry,
47,
11285-11299.
|
 |
|
|
|
|
 |
M.Peipp,
J.J.Lammerts van Bueren,
T.Schneider-Merck,
W.W.Bleeker,
M.Dechant,
T.Beyer,
R.Repp,
P.H.van Berkel,
T.Vink,
J.G.van de Winkel,
P.W.Parren,
and
T.Valerius
(2008).
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
|
| |
Blood,
112,
2390-2399.
|
 |
|
|
|
|
 |
P.J.Carter,
and
P.D.Senter
(2008).
Antibody-drug conjugates for cancer therapy.
|
| |
Cancer J,
14,
154-169.
|
 |
|
|
|
|
 |
P.Prabakaran,
B.K.Vu,
J.Gan,
Y.Feng,
D.S.Dimitrov,
and
X.Ji
(2008).
Structure of an isolated unglycosylated antibody C(H)2 domain.
|
| |
Acta Crystallogr D Biol Crystallogr,
64,
1062-1067.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Q.Zhou,
S.Shankara,
A.Roy,
H.Qiu,
S.Estes,
A.McVie-Wylie,
K.Culm-Merdek,
A.Park,
C.Pan,
and
T.Edmunds
(2008).
Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function.
|
| |
Biotechnol Bioeng,
99,
652-665.
|
 |
|
|
|
|
 |
S.L.Sazinsky,
R.G.Ott,
N.W.Silver,
B.Tidor,
J.V.Ravetch,
and
K.D.Wittrup
(2008).
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors.
|
| |
Proc Natl Acad Sci U S A,
105,
20167-20172.
|
 |
|
|
|
|
 |
S.Miyakawa,
Y.Nomura,
T.Sakamoto,
Y.Yamaguchi,
K.Kato,
S.Yamazaki,
and
Y.Nakamura
(2008).
Structural and molecular basis for hyperspecificity of RNA aptamer to human immunoglobulin G.
|
| |
RNA,
14,
1154-1163.
|
 |
|
|
|
|
 |
S.Y.Wang,
E.Racila,
R.P.Taylor,
and
G.J.Weiner
(2008).
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
|
| |
Blood,
111,
1456-1463.
|
 |
|
|
|
|
 |
S.Y.Wang,
and
G.Weiner
(2008).
Complement and cellular cytotoxicity in antibody therapy of cancer.
|
| |
Expert Opin Biol Ther,
8,
759-768.
|
 |
|
|
|
|
 |
T.I.Arnon,
J.T.Kaiser,
A.P.West,
R.Olson,
R.Diskin,
B.C.Viertlboeck,
T.W.Göbel,
and
P.J.Bjorkman
(2008).
The crystal structure of CHIR-AB1: a primordial avian classical Fc receptor.
|
| |
J Mol Biol,
381,
1012-1024.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
V.Oganesyan,
C.Gao,
L.Shirinian,
H.Wu,
and
W.F.Dall'Acqua
(2008).
Structural characterization of a human Fc fragment engineered for lack of effector functions.
|
| |
Acta Crystallogr D Biol Crystallogr,
64,
700-704.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Wei,
C.Li,
W.Huang,
B.Li,
S.Strome,
and
L.X.Wang
(2008).
Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation.
|
| |
Biochemistry,
47,
10294-10304.
|
 |
|
|
|
|
 |
J.M.Kneller,
T.Ehlen,
J.P.Matisic,
D.Miller,
D.Van Niekerk,
W.L.Lam,
M.Marra,
R.Richards-Kortum,
M.Follen,
C.Macaulay,
and
S.J.Jones
(2007).
Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling.
|
| |
Biomark Insights,
2,
447-461.
|
 |
|
|
|
|
 |
P.Li,
N.Jiang,
S.Nagarajan,
R.Wohlhueter,
P.Selvaraj,
and
C.Zhu
(2007).
Affinity and kinetic analysis of Fcgamma receptor IIIa (CD16a) binding to IgG ligands.
|
| |
J Biol Chem,
282,
6210-6221.
|
 |
|
|
|
|
 |
R.Jefferis
(2007).
Antibody therapeutics: isotype and glycoform selection.
|
| |
Expert Opin Biol Ther,
7,
1401-1413.
|
 |
|
|
|
|
 |
R.S.Davis
(2007).
Fc receptor-like molecules.
|
| |
Annu Rev Immunol,
25,
525-560.
|
 |
|
|
|
|
 |
C.Ferrara,
F.Stuart,
P.Sondermann,
P.Brünker,
and
P.Umaña
(2006).
The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms.
|
| |
J Biol Chem,
281,
5032-5036.
|
 |
|
|
|
|
 |
C.Sommereyns,
and
T.Michiels
(2006).
N-glycosylation of murine IFN-beta in a putative receptor-binding region.
|
| |
J Interferon Cytokine Res,
26,
406-413.
|
 |
|
|
|
|
 |
E.R.Sprague,
C.Wang,
D.Baker,
and
P.J.Bjorkman
(2006).
Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging.
|
| |
PLoS Biol,
4,
e148.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.T.Teusner,
C.Goddard,
D.A.Belford,
V.Dunaiski,
and
B.C.Powell
(2006).
Identification of a novel FcgammaRIII receptor that is up-regulated in fetal wound healing.
|
| |
Wound Repair Regen,
14,
405-412.
|
 |
|
|
|
|
 |
K.Barbin,
J.Stieglmaier,
D.Saul,
K.Stieglmaier,
B.Stockmeyer,
M.Pfeiffer,
P.Lang,
and
G.H.Fey
(2006).
Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies.
|
| |
J Immunother (1997),
29,
122-133.
|
 |
|
|
|
|
 |
M.M.Gomes,
and
A.B.Herr
(2006).
IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential.
|
| |
Springer Semin Immunopathol,
28,
383-395.
|
 |
|
|
|
|
 |
A.Nakamura,
K.Akiyama,
and
T.Takai
(2005).
Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer.
|
| |
Expert Opin Ther Targets,
9,
169-190.
|
 |
|
|
|
|
 |
A.Verdoliva,
D.Marasco,
A.De Capua,
A.Saporito,
P.Bellofiore,
V.Manfredi,
R.Fattorusso,
C.Pedone,
and
M.Ruvo
(2005).
A new ligand for immunoglobulin g subdomains by screening of a synthetic peptide library.
|
| |
Chembiochem,
6,
1242-1253.
|
 |
|
|
|
|
 |
I.Matsumoto,
H.Zhang,
Y.Muraki,
T.Hayashi,
T.Yasukochi,
Y.Kori,
D.Goto,
S.Ito,
A.Tsutsumi,
and
T.Sumida
(2005).
A functional variant of Fcgamma receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies.
|
| |
Arthritis Res Ther,
7,
R1183-R1188.
|
 |
|
|
|
|
 |
J.Hunt,
R.L.Beavil,
R.A.Calvert,
H.J.Gould,
B.J.Sutton,
and
A.J.Beavil
(2005).
Disulfide linkage controls the affinity and stoichiometry of IgE Fcepsilon3-4 binding to FcepsilonRI.
|
| |
J Biol Chem,
280,
16808-16814.
|
 |
|
|
|
|
 |
M.A.Schneider,
H.Brühl,
A.Wechselberger,
J.Cihak,
M.Stangassinger,
D.Schlöndorff,
and
M.Mack
(2005).
In vitro and in vivo properties of a dimeric bispecific single-chain antibody IgG-fusion protein for depletion of CCR2+ target cells in mice.
|
| |
Eur J Immunol,
35,
987-995.
|
 |
|
|
|
|
 |
R.Jefferis
(2005).
Glycosylation of recombinant antibody therapeutics.
|
| |
Biotechnol Prog,
21,
11-16.
|
 |
|
|
|
|
 |
T.Takai
(2005).
Fc receptors and their role in immune regulation and autoimmunity.
|
| |
J Clin Immunol,
25,
1.
|
 |
|
|
|
|
 |
T.Xu,
N.J.Logsdon,
and
M.R.Walter
(2005).
Structure of insect-cell-derived IL-22.
|
| |
Acta Crystallogr D Biol Crystallogr,
61,
942-950.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.R.Sprague,
W.L.Martin,
and
P.J.Bjorkman
(2004).
pH dependence and stoichiometry of binding to the Fc region of IgG by the herpes simplex virus Fc receptor gE-gI.
|
| |
J Biol Chem,
279,
14184-14193.
|
 |
|
|
|
|
 |
G.Bertrand,
E.Duprat,
M.P.Lefranc,
J.Marti,
and
J.Coste
(2004).
Characterization of human FCGR3B*02 (HNA-1b, NA2) cDNAs and IMGT standardized description of FCGR3B alleles.
|
| |
Tissue Antigens,
64,
119-131.
|
 |
|
|
|
|
 |
J.M.Woof,
and
D.R.Burton
(2004).
Human antibody-Fc receptor interactions illuminated by crystal structures.
|
| |
Nat Rev Immunol,
4,
89-99.
|
 |
|
|
|
|
 |
K.Wenig,
L.Chatwell,
U.von Pawel-Rammingen,
L.Björck,
R.Huber,
and
P.Sondermann
(2004).
Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG.
|
| |
Proc Natl Acad Sci U S A,
101,
17371-17376.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
P.Maillard,
J.P.Lavergne,
S.Sibéril,
G.Faure,
F.Roohvand,
S.Petres,
J.L.Teillaud,
and
A.Budkowska
(2004).
Fcgamma receptor-like activity of hepatitis C virus core protein.
|
| |
J Biol Chem,
279,
2430-2437.
|
 |
|
|
|
|
 |
A.B.Herr,
E.R.Ballister,
and
P.J.Bjorkman
(2003).
Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc.
|
| |
Nature,
423,
614-620.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Fernández,
and
H.A.Scheraga
(2003).
Insufficiently dehydrated hydrogen bonds as determinants of protein interactions.
|
| |
Proc Natl Acad Sci U S A,
100,
113-118.
|
 |
|
|
|
|
 |
A.Fernández,
and
R.Scott
(2003).
Dehydron: a structurally encoded signal for protein interaction.
|
| |
Biophys J,
85,
1914-1928.
|
 |
|
|
|
|
 |
B.A.Wurzburg,
and
T.S.Jardetzky
(2003).
The IgA receptor complex: a two-for-one deal.
|
| |
Nat Struct Biol,
10,
585-587.
|
 |
|
|
|
|
 |
B.D.Wines,
A.Gavin,
M.S.Powell,
M.Steinitz,
R.R.Buchanan,
and
P.Mark Hogarth
(2003).
Soluble FcgammaRIIa inhibits rheumatoid factor binding to immune complexes.
|
| |
Immunology,
109,
246-254.
|
 |
|
|
|
|
 |
B.Drescher,
T.Witte,
and
R.E.Schmidt
(2003).
Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity.
|
| |
Immunology,
110,
335-340.
|
 |
|
|
|
|
 |
G.M.Watt,
J.Lund,
M.Levens,
V.S.Kolli,
R.Jefferis,
and
G.J.Boons
(2003).
Site-specific glycosylation of an aglycosylated human IgG1-Fc antibody protein generates neoglycoproteins with enhanced function.
|
| |
Chem Biol,
10,
807-814.
|
 |
|
|
|
|
 |
H.J.Gould,
B.J.Sutton,
A.J.Beavil,
R.L.Beavil,
N.McCloskey,
H.A.Coker,
D.Fear,
and
L.Smurthwaite
(2003).
The biology of IGE and the basis of allergic disease.
|
| |
Annu Rev Immunol,
21,
579-628.
|
 |
|
|
|
|
 |
R.C.Monteiro,
and
J.G.Van De Winkel
(2003).
IgA Fc receptors.
|
| |
Annu Rev Immunol,
21,
177-204.
|
 |
|
|
|
|
 |
R.J.Pleass,
P.K.Dehal,
M.J.Lewis,
and
J.M.Woof
(2003).
Limited role of charge matching in the interaction of human immunoglobulin A with the immunoglobulin A Fc receptor (Fc alpha RI) CD89.
|
| |
Immunology,
109,
331-335.
|
 |
|
|
|
|
 |
Y.Ding,
G.Xu,
M.Yang,
M.Yao,
G.F.Gao,
L.Wang,
W.Zhang,
and
Z.Rao
(2003).
Crystal structure of the ectodomain of human FcalphaRI.
|
| |
J Biol Chem,
278,
27966-27970.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.B.Bodman-Smith,
A.J.Melendez,
I.Campbell,
P.T.Harrison,
J.M.Allen,
and
J.G.Raynes
(2002).
C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcgammaRI).
|
| |
Immunology,
107,
252-260.
|
 |
|
|
|
|
 |
M.Holland,
K.Takada,
T.Okumoto,
N.Takahashi,
K.Kato,
D.Adu,
A.Ben-Smith,
L.Harper,
C.O.Savage,
and
R.Jefferis
(2002).
Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis.
|
| |
Clin Exp Immunol,
129,
183-190.
|
 |
|
|
|
|
 |
P.M.Hogarth
(2002).
Fc receptors are major mediators of antibody based inflammation in autoimmunity.
|
| |
Curr Opin Immunol,
14,
798-802.
|
 |
|
|
|
|
 |
R.Atalay,
A.Zimmermann,
M.Wagner,
E.Borst,
C.Benz,
M.Messerle,
and
H.Hengel
(2002).
Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs.
|
| |
J Virol,
76,
8596-8608.
|
 |
|
|
|
|
 |
R.L.Shields,
J.Lai,
R.Keck,
L.Y.O'Connell,
K.Hong,
Y.G.Meng,
S.H.Weikert,
and
L.G.Presta
(2002).
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.
|
| |
J Biol Chem,
277,
26733-26740.
|
 |
|
|
|
|
 |
R.S.Davis,
G.Dennis,
M.R.Odom,
A.W.Gibson,
R.P.Kimberly,
P.D.Burrows,
and
M.D.Cooper
(2002).
Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family.
|
| |
Immunol Rev,
190,
123-136.
|
 |
|
|
|
|
 |
I.B.Rasmussen,
E.Lunde,
T.E.Michaelsen,
B.Bogen,
and
I.Sandlie
(2001).
The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.
|
| |
Proc Natl Acad Sci U S A,
98,
10296-10301.
|
 |
|
|
|
|
 |
J.V.Ravetch,
and
S.Bolland
(2001).
IgG Fc receptors.
|
| |
Annu Rev Immunol,
19,
275-290.
|
 |
|
|
|
|
 |
K.D.Corbett,
and
T.Alber
(2001).
The many faces of Ras: recognition of small GTP-binding proteins.
|
| |
Trends Biochem Sci,
26,
710-716.
|
 |
|
|
|
|
 |
K.Kato
(2001).
[Structural basis of the interaction between immunoglobulins and Fc receptors provided by NMR spectroscopy]
|
| |
Yakugaku Zasshi,
121,
345-354.
|
 |
|
|
|
|
 |
M.Hezareh,
A.J.Hessell,
R.C.Jensen,
J.G.van de Winkel,
and
P.W.Parren
(2001).
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.
|
| |
J Virol,
75,
12161-12168.
|
 |
|
|
|
|
 |
M.van Egmond,
C.A.Damen,
A.B.van Spriel,
G.Vidarsson,
E.van Garderen,
and
J.G.van de Winkel
(2001).
IgA and the IgA Fc receptor.
|
| |
Trends Immunol,
22,
205-211.
|
 |
|
|
|
|
 |
W.L.Martin,
A.P.West,
L.Gan,
and
P.J.Bjorkman
(2001).
Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.
|
| |
Mol Cell,
7,
867-877.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.Mimura,
P.Sondermann,
R.Ghirlando,
J.Lund,
S.P.Young,
M.Goodall,
and
R.Jefferis
(2001).
Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding.
|
| |
J Biol Chem,
276,
45539-45547.
|
 |
|
|
|
|
 |
J.Lund,
N.Takahashi,
A.Popplewell,
M.Goodall,
J.D.Pound,
R.Tyler,
D.J.King,
and
R.Jefferis
(2000).
Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I.
|
| |
Eur J Biochem,
267,
7246-7257.
|
 |
|
|
|
|
 |
T.L.Chapman,
A.P.Heikema,
A.P.West,
and
P.J.Bjorkman
(2000).
Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2).
|
| |
Immunity,
13,
727-736.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |